 SAN CARLOS, Calif., Sept. 06, 2022 GLOBE NEWSWIRE -- Iovance Biotherapeutics, Inc. NASDAQ: IOVA, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences in September: 